title: New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer.
abstract: Treatment of prostate cancer is continually evolving and new therapies have become available. However, the management of elderly patients is challenging due to their age and comorbidities. Androgen deprivation therapy remains the mainstay treatment of hormonal-sensitive disease. Nevertheless, when disease becomes resistant to castration, docetaxel-based chemotherapy represents the standard rescue therapy irrespective of patient age. Recently, chemotherapeutic agents such as cabazitaxel and hormonal therapies such as abiraterone acetate and enzalutamide have been shown to improve survival in patients with progression of disease before or following docetaxel. This review focuses on the safety and efficacy results of these new drugs in elderly patients.
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna - Italy.
authors.forename: Giovenzio
authors.initials: G
authors.lastname: Genestreti
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna - Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Di Battista
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna - Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Cavallo
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, AUSL Bologna-IRCCS Institute of Neurological Sciences, Bologna - Italy.
authors.forename: Alba A
authors.initials: AA
authors.lastname: Brandes
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents